ALOX5AP and ovarian cancer: One exciting but reasonable speculation is that combining immune-checkpoint blockade and ALOX5AP inhibitor therapies could synergistically halt ovarian cancer progression by simultaneously combating M2 macrophage infiltration and immune suppression in the ovarian cancer microenvironment.